Aura Biosciences, Inc. (AURA)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

6.54 on 9 Oct 2026

0 buys14 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$106.19M

Free cash flow

$85.19M

Return on equity

-77.6%

Return on capital

-65.1%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
16 Jun 2026	Gibney Anthony S See Remarks	Sold at will	$82.33K	4.6%
7 May 2026	Matrix Capital Management Company, LP 10% owner	Sold at will	$39.04M	100%
16 Apr 2026	Kilroy Conor See Remarks	Sold at will	$82.40K	5.1%
17 Feb 2026	de los Pinos Elisabet See Remarks	Sold at will	$241.10K	10.4%
17 Feb 2026	Hopkins Janet Jill Chief Medical Officer	Sold at will	$103.23K	8.1%
17 Feb 2026	Plavsic Mark Chief Technology Officer	Sold at will	$80.24K	8.1%

20out of 100

Profitability 0

Financial strength 60

Growth n/a

Insiders 0

Strongest on financial strength (60), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$40.06M

14 sales

Planned sales

under a 10b5-1 plan